Dermatology

puzzle pact

Biotech

Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan

Kaken will hand Alumis $40 million in the near term for the rights to a late-stage tyrosine kinase 2 inhibitor as a dermatology treatment in Japan.

James Waldron Mar 25, 2025 6:55am

Rebranding new name billboard

Canadian CRO Innovaderm rebrands to Indero

Mar 11, 2025 5:45am

Graphic image of a man climbing up a latter in front of a beige background with clouds and a blue splotch of sky

Canadian CRO seeks to grow in rheumatology field with new CEO

Feb 4, 2025 3:05pm

Sinking deal terminated sunk deal ends

Affibody regains drug, says ex-ally unable to capitalize on data

Feb 3, 2025 5:18am

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M

Apr 23, 2024 10:43am

Photo of a carnival ride that swings people in elevated chairs caught in motion

Oruka spins out of Paragon with assets, public listing and cash

Apr 3, 2024 7:30am